Paradise Community Center
Good Times.   Good Food.   Good Cause.
127 Pulpito • Zona Romantica • Puerto Vallarta • Jalisco, Mexico

Welcome to the Paradise Community Center!



The Paradise Community Center is an international, non-profit, faith-based community center located in the heart of Puerto Vallarta. The Paradise Community Center serves social, educational, cultural, not-for-profit, and other special events for the Puerto Vallarta community. Learn more... 

Why do we say: "Good times. Good food. Good cause"? Because the Paradise Community Center is a gathering place for good times. Because, in our expansive kitchen, we serve only the tastiest morsels of good food. Because we exist mainly to generate funds for a good cause: the mission of CompassioNet Impact Mexico.

 CompassioNet Impact Mexico (CNI) operates the
Paradise Community Center and serves thousands of 
guests annually.
After operating expenses, 100% of PCC profits benefit other important CNI programs.

Please help us help others and donate today! Thank you.


Donate Now Through!

Problems with our website? Email webmaster.

Adding resistance to a fitness can recruit your primary.

Back again Up Your Abs Work Problem your midsection like nothing you’ve seen prior with a fresh spin on a common ab builder. Adding resistance to a fitness can recruit your primary, strengthening your own body’s pillar – your torso, shoulders and hips. Adding the wire row to a lateral pillar bridge, ‘feels as though someone’s pressing you forwards and backwards,’ says functionality trainer Anthony Slater instructions for use . That’ll increase your strength during your pillar. The Benefit You’ll create a more steady midsection, so that you can stand taller and perform better in sports activities. Continue reading

Arterial spin labeling.

Arterial spin labeling shows areas of brain activity in chronic low back again pain patients Study from Brigham and Women’s Hospital runs on the new imaging technique, arterial spin labeling, showing the areas of the brain that are activated when individuals with low back discomfort possess a worsening of their usual, chronic discomfort here . In the August problem of the journal Anesthesiology This analysis is published. ‘This study is a first step towards providing equipment to objectively describe someone’s chronic discomfort which really is a subjective knowledge. Continue reading

According to a Penn Condition study.

American children not drinking enough milk American children are drinking too little milk and what they are consuming is certainly too high in fat, according to a Penn Condition study. There exists a strong correlation between dairy consumption and calcium, says Sibylle Kranz, assistant professor of dietary sciences. Since there is calcium in fortified orange juice, for instance, it is not as bioavailable as that within milk click here . She notes that people need to consider calcium with supplement D plus some protein for ideal use in the body. Kranz, working with Po-Ju Lin, doctoral student and David A. Wagstaff, statistician, looked at children’s typical daily dairy intake and compared it with that recommended by the U.S. Continue reading

Amylin disappointed with U achat kamagra.

Amylin disappointed with U.S. District Court’s ruling in BYETTA preliminary injunction Amylin Pharmaceuticals, Inc achat kamagra . today issued the next statement regarding the decision of the United States District Courtroom for the Southern District of California to deny its motion for a preliminary injunction to enjoin Eli Lilly and Company from participating in anticompetitive activity and breaching its diabetes collaboration agreement with Amylin. ‘We are disappointed by the Court’s decision not to issue an initial injunction, which Amylin requested to prevent Lilly from proceeding with its plans to use the same sales push to market both exenatide and Boehringer Ingelheim GmbH’s competing medication, linagliptin.’ The entire order is being filed on Amylin’s Current Survey on Form 8-K with the Securities and Exchange Commission. .. Continue reading

The principal and most powerful of the catechins or flavonoids.

Antioxidant compound found in green tea leaves will not clear established plaque Using a technique that enables them to study both early and advanced levels of arterial plaque buildup in the same mice, researchers at Cedars-Sinai INFIRMARY found that an antioxidant compound within green tea leaves will not clear established plaque but will inhibit the development of new deposits. Several components of green tea extract leaves are known to have natural properties that counteract the harmful ramifications of oxidation in the bloodstream eternal youth . In fact, the principal and most powerful of the catechins or flavonoids, EGCG , has been shown to provide some protection against the development of irritation, tumors and the brand new arteries that support tumor growth. Continue reading

And the Estate of Dr.

Atkins high-fat-low-carbohydrate diet may have caused severe cardiovascular disease Today against Atkins Nutritionals A Florida businessman filed match, Inc., and the Estate of Dr. Robert C effekter av tadalafil . He’s seeking a courtroom injunction banning Atkins Nutritionals from advertising its products with out a caution of potential health threats and requests compensatory damages. Before Gorran continued the Atkins diet plan, his cholesterol rate was a wholesome 146 and a center scan demonstrated he was free from coronary artery disease. He continued in the diet due to the assurances in the Atkins diet plan Internet and books site. Continue reading

Leading suppliers of innovative analytical instrumentation.

Analytik announces Ireland and UK release of the SciAps Inspector 500 SWIR Raman for the pharmaceutical industry Analytik, leading suppliers of innovative analytical instrumentation, announce the SciAps Inspector 500 SWIR Raman system for the pharmaceutical industry. The Inspector 500, featuring shortwave-infrared Raman technology, offers a new choice in handheld Raman analysers. The Inspector 500 includes a novel 1030 nm laser and proprietary detector . Continue reading

Alport syndrome: an interview with Dr Paul Grint.

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus By April Cashin-Garbutt Interview conducted, BA Hons insights from industryDr. Paul GrintCMO, Regulus What’s Alport syndrome and who does it affect? Alport Syndrome was described by a physician called Cecil Alport initial, back in the late 1920s joint infections . It's a genetic disease that affects a certain type of collagen involved in the working of the kidney, the ear canal, and the eye. Mainly, when people discuss Alport Syndrome, they're considering kidney disease, but numerous these patients do also have impaired hearing and impaired eyesight. As a genetic disease, Alport syndrome can affect anybody in the genetic inheritance collection concerned. Probably about 75 percent of the transmission is what we call X-linked, therefore inherited through the X chromosome. The condition therefore affects males. In the rest of cases, the condition is not X-linked and the inheritance price is comparable between males and females. Depending on the character of the genetic mutation, this at which the syndrome starts to trigger symptoms varies. Overall, you have a tendency to see patients initially presenting with symptoms of renal disease at some true point in their teens. Quite often, they shall have hematuria or blood in the urine, but are usually feeling well, which is the reason they go to the doctor usually. There's a cascade of investigations the doctor undertakes because, so long as no urinary tract infection is present, healthy people shouldn’t have blood or protein in their urine. How much is well known about the sources of Alport syndrome currently? Quite a great deal is in fact known about the causes in terms of the genetic defect impacting particular collagen molecules. Certain genes code for those molecules, which have become important in regards to to the anatomy of the kidney. The collagen molecules are assembled in an arrangement known as the basement membrane, which is crucial in enabling the kidney to operate as a highly effective filter of waste products. In Alport syndrome, because the basement membrane collagen correctly is not constructed, the kidneys basically neglect to function properly and, over time, irritation and therefore fibrosis develop. Why is the condition understood? We understand quite a complete lot about the disease procedure and about the genetics, but Alport syndrome is not an extremely common disease and there are no authorized therapeutic interventions for these sufferers. Basically, patients are monitored and diagnosed, perhaps originally by a pediatric endocrinologist, and described major centers then. For example, in the united kingdom, I believe you'll find the fantastic Ormond Street includes a lot of experience because teens identified as having the condition are looked after there. The teens are monitored and eventually their renal function declines to the main point where they want dialysis or a kidney transplant. However, one of the ways that we understand disease inside our industry is to review it in comprehensive controlled clinical studies. What are the main renal function markers and why is it vital that you research how they decline in Alport syndrome individuals over time? There are a number of different markers that we follow to assess kidney function generally. The kidney can be an important organ in your body for filtering waste products and you can really just gauge the levels of those, both in the blood and the urine. One cases is normally creatinine, a by-product of muscle fat burning capacity. The levels of creatinine are more developed in a sound body with normal kidney function generally. Creatinine is usually excreted by the kidney into the urine actively, but as the kidney function declines, the creatinine level in the bloodstream rises. Creatinine is therefore an excellent marker of kidney function and requires only a simple blood check. Another waste product that is relatively simple to test for is blood urea nitrogen . This is actually the level of nitrogen in the blood that comes from urea, the breakdown product of protein. Urea is excreted through the kidney and as kidney function declines, the BUN level in the bloodstream rises. We are able to also assess kidney function pretty accurately using something called the glomerular filtration rate , which assesses the function of the glomerulus, a framework which is involved with handling the excretion of waste from your body primarily. There are different means of screening the GFR. Then, you measure the known degrees of that chemical in both blood and the urine over time. In addition, there are various other biomarkers one can look at such as beta-2 microglobulin. As we're employed in the microRNA space and understand that we are able to detect microRNAs both in blood and in urine, we'll also be seeking at those microRNAs within our trials. Related StoriesGlan Clwyd Hospital N Wales invest in Esaote's G-Scan MRI device for weight-bearing scanningMedUni Vienna experts discover genetic cause of a rare diseaseUnderstanding how schizophrenia affects workings of the brainFinally, a renal biopsy can also be used to assess renal function. A needle is used to take a little sample of cells from the kidney, which is after that examined histologically with unique stains to assess the amount of inflammation, fibrosis or whatever is normally in it. However, this is a distressing procedure for the patient in fact it is often just performed to confirm diagnosis in situations of chronic kidney disease. Most of the other markers I defined involve either a bloodstream or urine sample simply, so they are applied to a more schedule basis. What do you consider would be the main problems in increasing our knowledge of Alport syndrome? I believe we have a good sense of the condition in terms of its inheritance pattern and exactly what happens to individuals who develop the disease. In terms of therapeutic intervention, we need to create the endpoints that could be found in a clinical study to assess the effects of the intervention on confirmed measure. Certainly, in this patient populace the most popular outcome would be to arrest the disease and stop its progression. If that’s not possible, the aim could be to significantly sluggish disease progression in order that rather than patients developing end-stage renal disease by their past due 20s, it may be delayed until the past due 30s, 40s, or even later. We have to look at measures that we can analyze as part of the clinical study reproducibly, perhaps by examining the difference between an organization receiving treatment and a group not receiving treatment. That's basically what you want to try and do, but the formal procedure for getting a drug approved and establishing those endpoints needs to be agreed both in the US with the FDA and with the European Medicines Agency in Europe, in order that regulators concur that the endpoints used in the clinical protocols are suitable for assessing the efficacy of the medication. What do you consider the future keeps for Alport syndrome patients? I think the good news is that, as brand-new therapeutic interventions are introduced to these orphan disease populations, people shall begin paying more attention to the patients also to the disease. There are some great patient organizations that want to educate people about how Alport syndrome is a genetic disease that may be regarded as a possible analysis when there are even the earliest signs of kidney disease. The exams used to identify Alport syndrome are not at all hard genetic tests, yet several healthcare systems in america will not reimburse for all those tests. I think that as this individual group starts to create noise, it could push for earlier analysis. I believe the doctors who look after these patients can really start to consider working with the patients and with companies like us, in regards to to studying therapeutic interventions. I think overall, people shall pay more focus on the disease, which at the end of the day is usually a great part of terms of the individuals' outcome. We've started our Athena study, a natural history study that is currently enrolling patients into a formal clinical protocol. We are generally testing these individuals to monitor their renal function and a genuine number of other things over time, so we are able to assess what the natural progression of the condition is in a potential manner. That research has started now in america. We hope we are able to use the information out of this study to talk with both FDA and EMA concerning endpoints and possible designs for a Phase 2 study, which we wish to start in regards to a year from now. We're currently trying to gather all of the right paperwork to construct an Investigational New Medication application. We will also be able to file all of that paperwork in Europe later on. The IND will allow us to do some initial function in the US using healthy volunteers to greatly help us better understand the kinetics of this drug. You want to examine different subcutaneous dosages to observe how much enters the bloodstream and how much can be excreted through the kidney. We'll carry out some of that ongoing work over the first half of next year, and then continue steadily to work on the Phase 2 design with many of the essential opinion leaders and with regulatory organizations. That's our plan for the near future. Where can readers find more information? Users can discover more information at the Regulus site, At the bottom right hands part of the homepage, there is usually information regarding the Athena medical trial where people can also link to the website. That site is basically because really beneficial to look at, as we discussed, this is a patient population that hasn't really been involved with clinical study before. The web site provides background information about being a individual in a scientific trial. We need the patients' support and commitment to come quickly to their clinic visits, consent to the blood testing, and other things. We need the clinical study to become a partnership between us, the sufferers and the doctors caring for these sufferers, if we're going to be successful in moving the scientific program ahead. About Dr Paul Grint Dr. In June 2014 with over two decades of experience in biologics and small molecule development Grint joined Regulus, like the successful commercialization of several commercial items in oncology, immunology and anti-infectives in both household and international markets. Prior to joining Regulus, Dr. Grint was President of Cerexa, Inc., a wholly-possessed subsidiary of Forest Laboratories, Inc., where he was in charge of the oversight of anti-infective product development. To that Prior, Dr. Grint offered as Senior Vice President of Analysis at Forest Analysis Institute, Inc., Chief Medical Officer at Kalypsys, Inc., and Senior Vice Chief and President Medical Officer at Zephyr Sciences, Inc., and he also served in identical executive level positions at Pfizer Inc., IDEC Pharmaceuticals Company, and Schering-Plough Company. Dr. Dr. Grint is definitely a Fellow of the Royal College of Pathologists, a known member of many professional and medical societies, and the co-author or author of over fifty scientific publications. Continue reading

Todays office workplaces are designed as ergonomically as possible Nevertheless ditt sexliv.

Today’s office workplaces are designed as ergonomically as possible Nevertheless, after hours of bent to stand on a desk, it stretch stretch ditt sexliv . Your legs and relax your back spending is an entire day in practically the same cramped position is a very exhausting affair.

Scientists examine toxicity of medicinal plants in PeruMany developing countries rely on traditional medicine as an accessible and affordable treatment option for human diseases. But until now, scientific data the potential toxicity to evaluate the potential toxicity of medicinal plant species in Peru. Scientists from the William L. Brown Center of the Missouri Botanical Garden in St. Louis conducted a study with brine shrimp the toxicity the toxicity of 341 Northern Peru plant species commonly ingested in traditional medicine. Their results showed over 24 % of water extracts of the plants and produced 76 % of the alcoholic extracts from the plant contained increased toxicity. The results underscore the need for traditional methods in different toxicity to consider when selecting the most suitable solvent for the production of a pharmaceutical cure. In the U.S., by grants from the National Institutes of Health MHIRT program by San Diego State University and published in the Journal of Ethnopharmacology. Continue reading